IL-5 CAR-T therapy for eosinophilic leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This phase 1 trial tests a new treatment called IL-5 CAR-T for patients with eosinophilic leukemia that has not responded to or has returned after standard therapy. It uses your own immune cells that are modified to target and kill cancer cells that have a specific marker called CD125.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old
- Have eosinophilic leukemia that has not improved with standard treatments or has come back within 6 months
- Have at least 50% of your leukemia cells showing a specific target (CD125)
- Have adequate organ function (liver, heart, and oxygen levels) as determined by blood tests and scans
- Have an estimated life expectancy of more than 3 months and a good performance status (able to care for yourself)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
This trial tests a new CAR-T cell therapy that targets a protein called CD19 on leukemia cells. It's designed for people with relapsed or refractory B-cell acute lymphoblastic leukemia (a type of blood cancer) that hasn't responded to standard treatments.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
This trial tests an experimental treatment using your own immune cells (called CAR-T cells) that are specially designed to find and destroy leukemia cells that have a specific marker called CD123. It is for people with acute myeloid leukemia (AML) that has not responded to treatment or has returned, and who have limited other options.
This trial tests a new type of immune cell therapy (called CAR-T) that targets two proteins, CD5 and CD7, on the surface of T-cell leukemia or lymphoma cells. It may be an option for people whose cancer came back or didn't respond to standard treatment.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.